Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03552523 · ClinicalTrials.gov registry record · NA

The Set-Point Study for Type 2 Diabetes: Evaluating the Use of an Insulin Only Bionic Pancreas System in Type 2 Diabetes

A NA study of Type 2 Diabetes Mellitus, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
16
Enrollment target
1
Study location

NCT03552523 is a NA study of Type 2 Diabetes Mellitus that has completed, run by Massachusetts General Hospital. The registered enrollment target is 16 participants, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03552523, a NA study of Type 2 Diabetes Mellitus, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

Our goal is to conduct an outpatient study testing the bionic pancreas in the insulin-only configuration at a set-point of 100 mg/dl in 10 adult (≥ 18 years of age) subjects with type 2 diabetes in a random-order crossover study versus usual care with daily injections or an insulin pump.

Conditions Studied

Interventions

  • OTHER Usual Care
  • DEVICE Bionic Pancreas

Study Locations (1)

Massachusetts

  • Diabetes Research Center - Boston

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2017-07-28
Est. Completion 2018-03-29
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT03552523

The ClinicalTrials.gov registry entry for NCT03552523 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.

NCT03552523 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03552523 about?

NCT03552523 is a clinical study titled "The Set-Point Study for Type 2 Diabetes: Evaluating the Use of an Insulin Only Bionic Pancreas System in Type 2 Diabetes". Our goal is to conduct an outpatient study testing the bionic pancreas in the insulin-only configuration at a set-point of 100 mg/dl in 10 adult (≥ 18 years of age) subjects with type 2 diabetes in a random-order crossover study versus usual care with daily injections or an insulin pump.

What is the current status of trial NCT03552523?

This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2017-07-28. Estimated completion is 2018-03-29.

What conditions does trial NCT03552523 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.

What interventions are being tested in trial NCT03552523?

The interventions under investigation include: Usual Care (OTHER), Bionic Pancreas (DEVICE).

Who is sponsoring clinical trial NCT03552523?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03552523 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.